148 results about "Cardiac glycoside" patented technology

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating hypoxia-related pathological conditions, such as Alzheimer's Disease, and those involving excessive angiogenesis, especially those non-cancer pathological conditions. The invention provides the use of Na+ / K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents for treating such conditions. The invention also relates to the use of cardiac glycoside inhibitors / antagonists as reagents, pharmaceutical formulations, or in kits and methods for treating conditions arising from excessive amount of cardiac glycosides, including all symptoms of digitalis poisoning, depression, hypertension, etc. The pharmaceutical formulation of the invention may be delivered to a patient either systemically or locally, or both. The pharmaceutical formulations of the invention may be delivered either in one dose, or continuously over a sustained period of time using, for example, sustained drug delivery devices.

A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as Nerium oleander, is extracted by SCF extraction. The extract can also contain one or more other SCF extractable pharmacologically active agents. The composition can be used to treat a wide range of disorders that are therapeutically responsive to a cardiac glycoside.

A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside to a subject. The cardiac glycoside can be present in a dosage form.

The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as Nerium oleander, through use of aloe. It further provides for compositions resulting from such extractions, pharmaceutical compositions, cosmetic compositions, and methods of treating skin conditions.

A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+e / K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers. The subject Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.

The invention belongs to the technical field of medicaments and in particular relates to cardiac glycoside compounds with a general formula (I), as well as derivatives, stereoisomers, a racemic mixture or a non-racemic mixture of the stereoisomers and pharmaceutically acceptable acid addition salts or solvates, wherein R1 is CH3, CHO or CH2OH; R2 is H or a linear saccharide chain or a branched saccharide chain, the linear saccharide chain or the branched saccharide chain is formed by saccharides; and these acids comprise inorganic acids like hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, nitric acid, carbonic acid and the like as well as organic acids like methanoic acid, acetic acid, succinic acid, citric acid, lactic acid, fumaric acid, tartaric acid, benzoic acid, p-methyl-benzenesulfonic acid, methylsulphonic acid, naphthalenesulfonic acid, gluconic acid and the like. The cardiac glycoside compounds can be obtained by separation from plants, in particular Streptocaulon plant juventas or Streptocaulon griffithii, by using multiple conventional separating means or obtained through synthesis, semisynthesis or bioconversion means. These compounds have excellent inhibiting and treatment effects on multiple tumor cells.

Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.

A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+ / K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain or proscillaridin, etc.).

The present invention pertains to methods of extracting cardiac glycosides from cardiac glycoside containing plant material, such as Nerium oleander, through use of aloe. It further provides for compositions resulting from such extractions, pharmaceutical compositions, cosmetic compositions, and methods of treating skin conditions.

A method of treating neurological condition in a subject by administration of a cardiac glycoside is provided. Alzheimer's disease, Huntington's disease or stroke are treated by administering a therapeutically effective amount of cardiac glycoside, and optionally triterpene(s), to a subject. The cardiac glycoside can be present in a dosage form.

A method for selecting action target of cardiac glucocide medicine by utilizing protein multistudy technique setting up model of cadiocytes culture and action on cadiocytes by cardiac glucocide, preparing protein sample, carrying two ¿C way gel electrophoresis and collecting image for analysis to obtain difference expression protein, using mass spectrum to determine difference protein peptide mass finger atlas to obtain DNA series for selecting out difference protein, verifying biological property of difference expression protein and using protein multistudy technique to select target of cardiac glucocide medicine.

The invention discloses an acer truncatum leaves health bagged tea, which comprises acer truncatum leaves, plateau greenleaf tea and semen cassiae, and is prepared through the steps of washing, spreading out for drying, water removing with vapor, kneading, drying, mixing and grinding, granulating, bagging, packaging and the like. By utilizing active substances which are rich in flavone, chlorogenic acid, tannin, cardiac glycosides and the like, health pharmacological active ingredients are not damaged, and the acer truncatum leaves health bagged tea can be used for treating and preventing coronary heart disease, angina pectoris, blood circulation disabled diseases and cardiovascular diseases and has actions of virus resistance, deflammation, cholagogue, removal of free radical of the human body, removal of liver heat, improvement of eyesight and the like.

The invention discloses quinquagenarian formula health rice flour and a preparation method thereof. The quinquagenarian formula health rice flour which is suitable for quinquagenarian and diabetes is prepared through puffing, crushing, sieving, blending, packaging and the like by taking 10-12 percent of embryos of giant embryo rice, 8-10 percent of wheat embryos, 15-18 percent of selenium-rich giant embryo coarse rice, 5-8 percent of black rice testa, 5-8 percent of red rice testa, 5-7 percent of kelp, 4-6 percent of laver, 5-8 percent of black sesame, 8-10 percent of lotus seeds, 8-10 percent of sunflower seeds, 8-12 percent of skimmed milk powder and 4-6 percent of isomaltose hypgather as raw materials. The health rice flour is rich in Gamma-aminobutyric acid, selenium, calcium, rice peptide, glutathione, flavonoids compounds, alkaloid, amino acids, microelements, vitamins, carotene, anthocyanin, cardiac glycoside and other functional components and has the capabilities of improving immunity and preventing senile dementia, caners, high blood pressure and other cardiovascular diseases after being eaten for a long time.

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+ / K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers.

A method for treating, preventing or ameliorating breast cancer is provided by administering a synergistic amount of digitoxin and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be paclitaxel. Methods for treating or preventing a neoplasia using a synergistic combination, and compositions of a synergistic combination of a cardiac glycoside and either actein or an extract of black cohosh comprising triterpene glycosides, and optionally another chemopreventive agent which may be a taxane are also provided. The compositions may also be used in a method for modulating Na+K+ATPase activity. In addition, a method for inhibiting the progression or development of breast cancer in vivo by administering either actein or an extract of black cohosh comprising triterpene glycosides and optionally at least one other chemoprotective agent is provided.

The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells. The reagent and pharmaceutical formulation of the invention relates to Na+ / K+-ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and / or solid dosage forms containing more than 1 mg of active ingredients.

Methods are provided for treating arrhythmia in a manner that minimizes undesirable side effects, comprising administration of a therapeutically effective minimal dose of an A1 adenosine receptor agonist with a therapeutically effective minimal dose of a beta blocker, calcium channel blocker, or a cardiac glycoside.

The invention provides a process for preparing periplocin which consists the steps of, (1) extracting medicinal material of Chinese silkvine bark, obtaining aqueous solution of Chinese silkvine bark, (2) carrying out macroporous resin absorption to the aqueous solution, eluting using 10-95% ethanol, collecting the elution position, concentrating and proceeding thin-layer chromatography, coloring with color-developing agent, collecting and merging positions with cardiac glycoside, (3) preparation and separation of liquid phase.

The invention discloses a preparation method of black sesame sealwort pills. The preparation method comprises the following raw materials by weight: 55-60% of black sesame, 15-20% of black bean, 5-10%of black rice, 5%-15% of sealwort and 10-15% of honey. In addition to the effects of benefiting the liver, tonifying the kidney, nourishing blood, moistening dryness, blacking the hair, preventing hair loss and beatifying of the black sesame obtained by the traditional process of steaming and sun burning for nine times respectively, the pills further contain manganese, zinc, copper and other inorganic salts as well as rich vitamin C, chlorophyll, anthocyanin, carotene, cardiac glycoside and other special ingredients. At the same time, the pills have the functions of preventing skin aging, clearing away heat and detoxification, nourishing blood and nourishing kidney, being anti-aging, regulating the immunity, regulating blood lipids, improving the memory and resisting the tumors.

The invention discloses giant embryo black kerneled rice and a method for breeding the giant embryo black kerneled rice. The method comprises the following steps of: selecting giant embryo mutation coarse rice grains by naked eyes from coarse rice of black kerneled rice M2 seeds by irradiating the black kerneled rice seeds which serve as a material by 60Co-gamma rays with a 380Gy dose according to the characteristic that the giant embryo character of rice is controlled by a single recessive gene, and the rice can be obtained by induced mutation, and breeding to form giant embryo black kerneled rice varieties by the selection of an agricultural technology and yield characters. By the method, the specific rice varieties which have the giant embryo character and a black seed coat character simultaneously can be bred simply and quickly, and the coarse rice of the giant embryo black kerneled rice is rich in special nutritional ingredients such as protein, fat, essential amino acid, anthocyanin, carotene, cardiac glycoside, dietary fibers, vitamins, gamma-aminobutyric acid and the like.

The present invention relates to combination therapies for melanoma, and in particular, metastatic melanoma. Drugs for use in such therapies in include MEK inhibitors combination with cardiac glycosides.

The invention relates to the medicine technology field, in particular relates to a new application of cardiac glycoside chemical compound having general formula (I) in preparing oncotherapy drug, wherein, R equals to 2-O-methyl-Beta-D-mycose, 6-deoxidation-Beta-D-gulose or 6-deoxidation-2-O-methyl-Beta-D-allose. The cardiac glycoside chemical compound can be obtained through a separation from upas in various conventional separation methods or be obtained through a synthesis or semisynthesis method.

The invention discloses an application of cedilanid in the preparation of anti-liver cancer and anti-bladder cancer medicaments; cedilanid is prepared into an injection, and is used for liver cancer and bladder cancer resistance; the concentration IC50 of the injection is 8*10-4 mmol / L. According to the invention, in an in-vitro experiment, the IC50 of cedilanid for liver cancer and bladder cancer cells is 8*10-4 mmol / L, and the effect is better than other cardiac glycoside medicaments; when compared with a common medicament of 5-fluorouracil with an IC50 of 1*10-1 mmol / L, cedilanid has a potency stronger by 100 times; in an antitumor experiment in animal body, cedilanid has a tumor inhibition rate of 34.26-48.43%; if application methods are proper, cedilanid is an ideal anticancer medicament.

The invention relates to a cardiac glycoside compound for inducing a nuclear receptor TR3 to express. The general formula of the compound of the invention is as follows: wherein, R1 is CH3, CHO or CH2OH; R2 is H or OH; R3 is H or OH; R4 is a linear sugar chain or a branch sugar chain consisted by saccharide. The cardiac glycoside compound of the invention can induce the nuclear receptor TR3 to express, thus being capable of being used as a revulsant to be applied to the preparation of drugs which are used for preventing and treating cancer, hepatitis, atherosclerosis, etc.

A method of treating viral infection, such as viral infection caused by a virus of the Filoviridae, Flaviviridae or Togaviriade family, is provided. A composition having at least one cardiac glycoside is used to treat viral infection. The composition can further include at least one triterpene.